Amphastar Pharmaceuticals ROE 2012-2024 | AMPH
Current and historical return on equity (ROE) values for Amphastar Pharmaceuticals (AMPH) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Amphastar Pharmaceuticals ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2024-06-30 |
$0.17B |
$0.71B |
25.35% |
| 2024-03-31 |
$0.15B |
$0.67B |
24.69% |
| 2023-12-31 |
$0.14B |
$0.64B |
23.10% |
| 2023-09-30 |
$0.14B |
$0.60B |
23.87% |
| 2023-06-30 |
$0.10B |
$0.59B |
18.78% |
| 2023-03-31 |
$0.09B |
$0.55B |
17.87% |
| 2022-12-31 |
$0.09B |
$0.53B |
18.08% |
| 2022-09-30 |
$0.08B |
$0.51B |
15.96% |
| 2022-06-30 |
$0.09B |
$0.50B |
19.62% |
| 2022-03-31 |
$0.08B |
$0.48B |
17.99% |
| 2021-12-31 |
$0.06B |
$0.45B |
14.05% |
| 2021-09-30 |
$0.04B |
$0.43B |
8.24% |
| 2021-06-30 |
$0.01B |
$0.47B |
2.42% |
| 2021-03-31 |
$0.00B |
$0.45B |
0.67% |
| 2020-12-31 |
$0.00B |
$0.45B |
0.45% |
| 2020-09-30 |
$0.01B |
$0.45B |
1.61% |
| 2020-06-30 |
$0.00B |
$0.44B |
0.93% |
| 2020-03-31 |
$0.05B |
$0.42B |
12.11% |
| 2019-12-31 |
$0.05B |
$0.43B |
11.71% |
| 2019-09-30 |
$0.05B |
$0.43B |
12.92% |
| 2019-06-30 |
$0.05B |
$0.43B |
13.97% |
| 2019-03-31 |
$0.00B |
$0.38B |
0.57% |
| 2018-12-31 |
$-0.01B |
$0.36B |
-1.77% |
| 2018-09-30 |
$-0.01B |
$0.34B |
-2.12% |
| 2018-06-30 |
$-0.01B |
$0.32B |
-2.74% |
| 2018-03-31 |
$-0.00B |
$0.33B |
-1.21% |
| 2017-12-31 |
$0.00B |
$0.33B |
1.21% |
| 2017-09-30 |
$0.00B |
$0.33B |
0.00% |
| 2017-06-30 |
$0.00B |
$0.33B |
1.22% |
| 2017-03-31 |
$0.01B |
$0.33B |
2.79% |
| 2016-12-31 |
$0.01B |
$0.33B |
3.17% |
| 2016-09-30 |
$0.02B |
$0.33B |
6.84% |
| 2016-06-30 |
$0.01B |
$0.31B |
4.73% |
| 2016-03-31 |
$0.00B |
$0.30B |
0.00% |
| 2015-12-31 |
$-0.00B |
$0.30B |
-1.05% |
| 2015-09-30 |
$-0.01B |
$0.28B |
-4.96% |
| 2015-06-30 |
$-0.02B |
$0.29B |
-5.67% |
| 2015-03-31 |
$-0.01B |
$0.28B |
-3.53% |
| 2014-12-31 |
$-0.01B |
$0.28B |
-3.98% |
| 2014-09-30 |
$-0.01B |
$0.28B |
-2.23% |
| 2014-06-30 |
$-0.00B |
$0.29B |
-0.51% |
| 2014-03-31 |
$0.01B |
$0.25B |
6.35% |
| 2013-12-31 |
$0.01B |
$0.25B |
19.05% |
| 2013-09-30 |
$0.01B |
$0.00B |
24.03% |
| 2013-06-30 |
$0.02B |
$0.00B |
29.18% |
| 2013-03-31 |
$0.01B |
$0.00B |
24.03% |
| 2012-12-31 |
$0.02B |
$0.23B |
30.90% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$2.469B |
$0.644B |
|
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
|
